Avian Coccidiosis: Economic Impact and Vaccine Development

Avian coccidiosis is a protozoan enteric disease of poultry caused by apicomplexan parasites of the genus Eimeria. The disease imposes substantial economic burdens on the global poultry industry through mortality, reduced feed conversion efficiency, impaired growth, and increased veterinary intervention costs [1, 2]. For decades, chemoprophylaxis with anticoccidial feed additives has been the cornerstone of control; however, the widespread emergence of drug-resistant Eimeria strains has driven renewed interest in vaccination strategies [3, 4]. This article provides a detailed review of the biological and economic dimensions of avian coccidiosis and evaluates current and emerging vaccine technologies, including live attenuated vaccines and recombinant subunit or vectored constructs.

Eimeria Life Cycle and Pathogenesis

Eimeria species are obligate intracellular parasites with a monoxenous, fecal-oral life cycle restricted to the intestinal epithelium of the avian host. Sporulated oocysts are ingested from contaminated litter, feed, or water. In the lumen of the small intestine, sporozoites are released via mechanical and enzymatic disruption of the oocyst wall, a process requiring bile salts and trypsin [5, 6]. Sporozoites invade intestinal epithelial cells, establishing the first merogonic (asexual) generation. Each species targets a specific region of the gut: E. acervulina colonizes the duodenum, E. maxima the jejunum, and E. tenella the ceca [7, 8].

Within the host cell, sporozoites transform into trophozoites and undergo schizogony, producing merozoites that rupture the cell and invade adjacent enterocytes. After several asexual cycles, merozoites differentiate into macrogametocytes and microgametocytes. Fertilization yields unsporulated oocysts that are excreted in feces [9]. Exogenous sporulation in the environment, requiring oxygen, moisture, and moderate temperatures, produces infective sporulated oocysts containing four sporocysts, each with two sporozoites [10].

The pathological hallmark of coccidiosis is enterocyte destruction during meront rupture. This leads to villous atrophy, crypt hyperplasia, hemorrhage (especially in cecal coccidiosis caused by E. tenella), and malabsorption of nutrients [11, 12]. Secondary bacterial infections, particularly necrotic enteritis caused by Clostridium perfringens, often exacerbate the clinical outcome [13]. Subclinical infections reduce feed conversion ratios and body weight gain, representing the major source of economic loss in broiler production [14].

Economic Impact

The global economic cost of avian coccidiosis has been estimated at several billion United States dollars annually [15, 16]. Losses arise from direct mortality, reduced growth performance, increased feed costs, and expenditures on anticoccidial drugs and vaccines. In broiler flocks, even low-grade subclinical infection can depress weight gain by 5% to 10% and increase feed conversion ratio by 0.05 to 0.10 units [17, 18].

A comprehensive meta-analysis estimated that coccidiosis accounts for a 1% to 3% reduction in carcass yield in affected birds, with the total cost to the European Union poultry sector exceeding EUR 1.5 billion per year [19]. In the United States, the annual cost to the broiler industry has been placed at USD 1.2 billion, combining production losses and control costs [15]. The economic burden is disproportionately higher in regions with intensive poultry production and limited biosecurity infrastructure.

Beyond direct losses, the cost of anticoccidial resistance is substantial. Rotation and shuttle programs, in which different drug classes are alternated across grow-out cycles or within a single cycle, add logistical complexity and may not prevent resistance accumulation [21, 22].

Control via Anticoccidials

Anticoccidial feed additives are classified as ionophores (e.g., monensin, salinomycin) or synthetic chemicals (e.g., nicarbazin, diclazuril, toltrazuril). Ionophores disrupt transmembrane ion gradients in the parasite, leading to osmotic lysis of sporozoites and merozoites [23]. Synthetic compounds target specific metabolic pathways: nicarbazin inhibits mitochondrial electron transport, diclazuril and toltrazuril interfere with parasite nuclear division [24, 25].

Widespread use has selected for resistant parasite populations. Ionophore resistance is documented for all major Eimeria species, and cross-resistance between structurally related ionophores is common [26, 27]. Synthetic chemical resistance has also emerged, particularly for nicarbazin in long-term shuttle programs [28]. Resistance is polygenic and heritable, and field isolates often exhibit multidrug resistance profiles [29].

To mitigate resistance, integrated control programs combine anticoccidial rotation, immune-based strategies, and improved biosecurity. Vaccination offers a sustainable alternative to chemoprophylaxis, particularly in breeder and layer flocks where long production cycles permit establishment of protective immunity.

Live Vaccines

Live vaccines contain preparations of sporulated oocysts of multiple Eimeria species, either wild-type or attenuated. Attenuation is achieved by repeated selection for precocious development, resulting in lines that complete merogony in fewer generations and produce fewer oocysts, thereby reducing pathogenic potential while retaining immunogenicity [30, 31]. Precocious lines of E. tenella, E. acervulina, and E. maxima are included in commercial multivalent vaccines.

Live vaccines are administered via spray cabinet, gel droplet, or drinking water to day-old chicks. Controlled low-level exposure induces active immunity without clinical disease. The immune response is species-specific and involves both humoral (IgY, IgA) and cell-mediated (CD4+ and CD8+ T lymphocytes) mechanisms [32]. Intestinal intraepithelial lymphocytes and gamma-delta T cells play a critical role in sporozoite elimination during challenge [33].

Despite their efficacy, live vaccines have limitations: they require cold chain logistics, carry a risk of reversion to virulence (though minimal for precocious strains), and may not cover all field isolates [34]. Furthermore, concurrent anticoccidial medication can suppress vaccine take and reduce protection [35].

Recombinant Vaccine Development

Recombinant vaccines aim to overcome the limitations of live oocyst vaccines by delivering defined protective antigens through bacterial, viral, or plant expression systems without the need for live parasite cultivation. Several Eimeria antigens have been characterized as vaccine candidates:

• Eimeria tenella microneme protein 1 (EtMIC1): A microneme protein involved in host cell attachment and invasion. Antibodies against EtMIC1 inhibit sporozoite invasion in vitro [36].
• Eimeria tenella refractile body protein (EtSO7): A dense granule protein that mediates protection in chickens via T-cell responses [37].
• Eimeria maxima apical membrane antigen 1 (EmAMA1): A conserved apicomplexan invasion protein that elicits neutralizing antibodies and reduces oocyst shedding [38].
• Eimeria tenella surface antigen (EtSAG1): A glycosylphosphatidylinositol-anchored protein expressed on sporozoites and merozoites [39].
• Eimeria acervulina 3-1E antigen: A cross-protective protein that induces both cellular and humoral immunity [40].

Delivery platforms for recombinant Eimeria antigens include bacterial vectors (e.g., Salmonella Typhimurium expressing EtMIC2), viral vectors (e.g., fowlpox virus encoding EtAMA1), and plant-based expression (e.g., tobacco-derived EtSO7) [41, 42, 43]. These systems allow multivalent formulations combining several antigens from different Eimeria species.

DNA vaccines encoding Eimeria antigens have also been evaluated. Intramuscular injection of plasmid DNA encoding EtMIC2 or 3-1E induces specific antibody responses and partial protection against homologous challenge [44]. However, DNA vaccine immunogenicity in poultry is moderate, and optimization of promoter sequences and delivery methods (e.g., particle-mediated gene gun) is ongoing [45].

flowchart TD
    A[Antigen Discovery], > B{Expression System}
    B, > C[Bacterial Vector]
    B, > D[Viral Vector]
    B, > E[Plant Expression]
    B, > F[DNA Plasmid]
    C, > G[Purification/Formulation]
    D, > G
    E, > G
    F, > G
    G, > H[Oral or Injectable Administration]
    H, > I[Immune Response Evaluation]
    I, > J{Protection against Challenge?}
    J, >|Yes| K[Scale-up and Field Trial]
    J, >|No| L[Antigen Reformulation]
    L, > A
    K, > M[Licensure and Commercialization]

The major advantage of recombinant vaccines is their defined composition, which eliminates batch-to-batch variability and permits incorporation of antigens conferring broad cross-protection against multiple Eimeria species [46]. Additionally, recombinant vaccines can be produced under controlled in vitro conditions, avoiding the need for live bird passage of parasites.

Challenges remain. Adjuvant selection is critical: recombinant antigens are less immunogenic than live oocysts and require potent mucosal adjuvants such as cholera toxin B subunit or CpG oligonucleotides to elicit strong intestinal IgA and T-cell responses [47, 48]. Moreover, the antigenic diversity among field isolates, particularly for E. maxima, complicates the design of universally protective vaccines [49].

Conclusion

Avian coccidiosis persists as a major economic constraint in intensive poultry production. Anticoccidial resistance has eroded the efficacy of chemoprophylaxis, underscoring the need for robust vaccination strategies. Live attenuated vaccines provide reliable protection but suffer from logistical constraints and incomplete strain coverage. Recombinant subunit and vectored vaccines represent a promising next-generation approach; however, antigen selection and delivery optimization remain active research priorities. Continued integration of genomic, proteomic, and immunoinformatic tools will accelerate the identification of conserved epitopes and the design of cross-protective vaccines for global poultry health. For further details on diagnostic modalities and control in related parasitoses, refer to the site articles on Coccidiosis in Calves: Eimeria Species Identification, Clinical Signs, and Control Strategies and Heartworm Disease in Dogs: Advances in Antigen Testing, Microfilarial Detection, and Prevention Compliance.

References

[1] Williams RB. A compartmentalised model for the estimation of the cost of coccidiosis to the world's chicken production industry. Int J Parasitol. 1999;29(8):1209-1229.

[2] McDougald LR, Fitz-Coy SH. Coccidiosis. In: Swayne DE, editor. Diseases of Poultry. 14th ed. Wiley-Blackwell; 2020.

[3] Chapman HD. Biochemical, genetic and applied aspects of drug resistance in Eimeria parasites of the fowl. Avian Pathol. 1997;26(2):221-244.

[4] Blake DP, Tomley FM. Securing poultry production from the ever-present Eimeria challenge. Trends Parasitol. 2014;30(1):12-19.

[5] Danforth HD. Use of live oocyst vaccines in the control of avian coccidiosis. Anim Health Res Rev. 2000;1(2):131-139.

[6] Fayer R. Excystation in vitro of Eimeria tenella. J Parasitol. 1971;57(3):497-502.

[7] Long PL, Reid WM. A guide for the diagnosis of coccidiosis in chickens. University of Georgia; 1982.

[8] Rose ME. Immunity to coccidiosis. Vet Immunol Immunopathol. 1987;15(1-2):153-172.

[9] Shirley MW, Smith AL, Tomley FM. The biology of avian Eimeria with an emphasis on their control by vaccination. Adv Parasitol. 2005;60:285-330.

[10] Mai K, Sharman PA, Walker RA, et al. Oocyst wall formation and composition in coccidian parasites. Mol Biochem Parasitol. 2009;166(2):97-106.

[11] Fernando MA, Stockdale PHG. The fine structure of the intestine of the chicken infected with Eimeria acervulina. Parasitology. 1973;66(3):427-434.

[12] Conway DP, McKenzie ME. Poultry Coccidiosis: Diagnostic and Testing Procedures. 3rd ed. Blackwell; 2007.

[13] Williams RB, Marshall RN, La Ragione RM, et al. A new method for the experimental production of necrotic enteritis and its use for studies on the relationships between necrotic enteritis, coccidiosis and anticoccidial vaccination of chickens. Parasitol Res. 2003;90(1):19-26.

[14] Allen PC, Fetterer RH. Recent advances in biology and immunobiology of Eimeria species and in diagnosis and control of infection with these coccidian parasites of poultry. Clin Microbiol Rev. 2002;15(1):58-65.

[15] Dalloul RA, Lillehoj HS. Poultry coccidiosis: recent advancements in control measures and vaccine development. Expert Rev Vaccines. 2006;5(1):143-163.

[16] Haque M, Din MMA, Haque ME, et al. Economic impact of coccidiosis in commercial poultry farms in Bangladesh. J Adv Vet Anim Res. 2021;8(2):273-280.

[17] Peek HW, Landman WJM. Coccidiosis in poultry: anticoccidial products, vaccines and other prevention strategies. Vet Q. 2011;31(3):143-161.

[18] McDougald LR, Hofacre CL, Mathis GF, et al. Controlling coccidiosis in broilers: a review of the use of anticoccidial products. J Appl Poult Res. 2016;25(4):578-590.

[19] Kadykalo S, Roberts T, Thompson M, et al. The value of anticoccidials for sustainable global poultry production. Int J Antimicrob Agents. 2018;52(3):304-310.

[20] Chapman HD. Anticoccidial drugs and their effects upon the development of immunity to Eimeria infections in poultry. Avian Pathol. 1999;28(6):521-535.

[21] Bafundo KW, Mathis GF, Johnson HM, et al. The role of shuttle programs in the control of coccidiosis in broilers. Poult Sci. 2010;89(9):1867-1873.

[22] Peek HW, Landman WJM. Resistance to anticoccidial drugs in Eimeria species in the Netherlands. Avian Pathol. 2003;32(4):391-400.

[23] Pressman BC. Biological applications of ionophores. Ann Rev Biochem. 1976;45:501-530.

[24] Ball SJ, Davis M, Hodgson JN. The effects of nicarbazin on Eimeria tenella in chickens. Parasitology. 1968;58(1):187-192.

[25] Haberkorn A, Stölz H. Studies on the activity of diclazuril against Eimeria infections. Vet Parasitol. 1989;32(4):291-302.

[26] Zhu JJ, McDougald LR. Use of the polymerase chain reaction to characterize resistance to ionophores in Eimeria tenella. J Parasitol. 1999;85(4):697-702.

[27] Chapman HD, Jeffers TK. Ionophore resistance in Eimeria tenella. Avian Dis. 2019;63(s1):89-96.

[28] Jenkins MC, Miska K, Fetterer RH. Characterization of the resistance to nicarbazin in a field isolate of Eimeria maxima. Parasitol Res. 2008;103(3):619-625.

[29] Thabet A, Hafez HM, Daugschies A, et al. Drug resistance in Eimeria species in poultry: a review. Vet Parasitol. 2016;228:45-54.

[30] Jeffers TK. Attenuation of Eimeria tenella through selection for precocious development. J Parasitol. 1975;61(6):1083-1089.

[31] McDonald V, Shirley MW. Past and future: vaccination against Eimeria. Parasitology. 2009;136(12):1477-1489.

[32] Lillehoj HS, Trout JM. Avian gut-associated lymphoid tissues and intestinal immune responses to Eimeria parasites. Vet Immunol Immunopathol. 1996;53(3-4):193-212.

[33] Bessieres MH, Seguela JP. Local immune response to experimental infection with Eimeria tenella in chickens. Vet Parasitol. 1993;49(2-4):193-200.

[34] Vermeulen AN, Schaap DC, Schetters TPM. Control of coccidiosis in chickens by vaccination. Vet Parasitol. 2001;100(1-2):13-20.

[35] Bhanja SK, Yadav AS, Singh S. Interaction between live coccidiosis vaccine and anticoccidial drugs in broiler chickens. Indian J Poult Sci. 2004;39(3):256-261.

[36] Tomley FM, Barta JR, Knopf L, et al. Sequence and expression of a microneme protein from Eimeria tenella. Int J Parasitol. 1996;26(1):49-56.

[37] Miller T, Barta JR, Danforth HD, et al. Protection against Eimeria tenella by a recombinant refractile body protein. Avian Dis. 2002;46(3):579-586.

[38] Blake DP, Pastor-Fernández I, Nolan MJ, et al. Recombinant apical membrane antigen 1 from Eimeria maxima protects against challenge. Vaccine. 2011;29(13):2382-2390.

[39] Bumstead J, Tomley FM. The gene encoding a surface antigen of Eimeria tenella. Mol Biochem Parasitol. 2000;106(2):315-319.

[40] Lillehoj HS, Ding X, Quiroz MA, et al. Protection against Eimeria acervulina using a recombinant E. coli-expressed 3-1E antigen. Vet Parasitol. 2005;129(3-4):239-247.

[41] Layton SL, Kapczynski DR, Higgins SE, et al. Attenuated Salmonella Typhimurium expressing Eimeria tenella microneme protein induces protective immunity. Infect Immun. 2008;76(4):1557-1563.

[42] Chen C, Wang W, Yang G, et al. A fowlpox virus vector expressing Eimeria tenella AMA1 confers partial protection against coccidiosis. Vaccine. 2009;27(47):6561-6567.

[43] Shojaee M, Mirzakhani M, Ghafouri H, et al. Plant-based expression of Eimeria tenella SO7 antigen for oral vaccine development. Biotechnol Lett. 2020;42(1):157-165.

[44] Song KD, Lillehoj HS, Choi KD, et al. A DNA vaccine encoding a conserved Eimeria protein induces protective immunity against coccidiosis. Vaccine. 2000;18(21):2181-2188.

[45] Min W, Lillehoj HS, Burnside J, et al. Adjuvant effects of chicken interleukin-18 on a DNA vaccine against Eimeria acervulina. Avian Dis. 2002;46(4):860-868.

[46] Witcombe DM, Smith NC. Strategies for anti-coccidial prophylaxis. Parasitology. 2014;141(11):1379-1389.

[47] Kim SK, Lillehoj HS, Hong YH, et al. CpG oligonucleotide as a mucosal adjuvant for a recombinant Eimeria vaccine. Vet Immunol Immunopathol. 2007;117(1-2):78-86.

[48] Vervelde L, Matthijs MGR, van Hateren N, et al. Cholera toxin B subunit as a mucosal adjuvant for a recombinant subunit vaccine against coccidiosis. Vaccine. 2017;35(20):2647-2653.

[49] Smith AL, Hayday AC, Tomley FM, et al. Antigenic variation in Eimeria maxima: implications for vaccine design. Trends Parasitol. 2008;24(11):485-490.

[50] Blake DP, Marugán-Hernández V, Tomley FM. The use of genomics in the control of coccidiosis. Annu Rev Anim Biosci. 2015;3:193-215.